Application of intestinal rothia recombinant flagellin to preparation of medicine for preventing and treating inflammatory bowel diseases

Abstract

The invention discloses application of intestinal rothia recombinant flagellin to the preparation of a medicine for preventing and treating inflammatory bowel diseases. The name of the intestinal rothia recombinant flagellin is RI-flagellin, and the intestinal rothia recombinant flagellin comprises His tag protein and fused protein of amino acid residues at a 1st site to a 497th site from an N endof the intestinal rothia recombinant flagellin. The invention provides application of the RI-flagellin to research and development of medicines for the inflammatory bowel diseases; an experiment of carrying out coloclysis on a mouse by utilizing 2,4,6-trinitrobenzene sulfonic acid (TNBS) to simulate the inflammatory bowel diseases finds out that the RI-flagellin has a remarkable prevention and treatment effect on the inflammatory bowel diseases. The intestinal rothia recombinant flagellin RI-flagellin can be used as an active component to prepare the medicine for preventing and treating the inflammatory bowel diseases.

Description

technical field

[0001] The invention belongs to the technical field of medicine preparation for inflammatory bowel disease, and in particular relates to the application of recombinant flagellin of Rosella enterica in the preparation of medicine for preventing and treating inflammatory bowel disease. Background technique

[0002] Inflammatory bowel disease (IBD) is a chronic non-specific intestinal inflammatory disease with unclear etiology and pathogenesis, including ulcerative colitis (UC) and Crohn's disease (Crohn's disease). disease, CD). In the past, the incidence of IBD in Asian countries was relatively low, and it was mainly concentrated in European and North American countries with better living standards. In recent years, with the improvement of human living standards, the incidence of IBD in different regions of the world has shown a continuous upward trend, indicating that IBD has become a global disease.

[0003] Current studies believe that the pathogenesis of...

Examples

Embodiment 1

[0048] Embodiment 1, preparation of Rosella enterica recombinant flagellin RI-flagellin

[0049] 1. Construction of a prokaryotic expression vector for the recombinant flagellin RI‐flagellin from Rosella enterica

[0050] 1) The gene encoding the recombinant flagellin RI-flagellin of Rosella enterica was artificially synthesized. Its nucleotide sequence is shown in SEQ NO.2 in the sequence listing, and its length is 1509bp. It was synthesized by Detai Biotechnology (Nanjing) Co., Ltd. The synthesized gene was detected by 2% agarose gel electrophoresis, and the detection result showed that the target gene of 1509 bp was obtained, which was consistent with the expected result.

[0051] 2) Construction of the recombinant expression vector Flagelllin-pET30a (+) (Flagellin represents the RI-flagellin coding sequence of the present invention)

[0052] a) PCR amplification of the RI-flagellin coding sequence

[0053] A 1509bp encoding gene of Rosia enterica recombinant flagellin wa...

Embodiment 2

[0104] Example 2. Verification of the prevention and treatment effect of Rosella enterica recombinant flagellin on inflammatory bowel disease

technical field

[0001] The invention belongs to the technical field of medicine preparation for inflammatory bowel disease, and in particular relates to the application of recombinant flagellin of Rosella enterica in the preparation of medicine for preventing and treating inflammatory bowel disease. Background technique

[0002] Inflammatory bowel disease (IBD) is a chronic non-specific intestinal inflammatory disease with unclear etiology and pathogenesis, including ulcerative colitis (UC) and Crohn's disease (Crohn's disease). disease, CD). In the past, the incidence of IBD in Asian countries was relatively low, and it was mainly concentrated in European and North American countries with better living standards. In recent years, with the improvement of human living standards, the incidence of IBD in different regions of the world has shown a continuous upward trend, indicating that IBD has become a global disease.

[0003] Current studies believe that the pathogenesis of...

Examples

Embodiment 1

[0048] Embodiment 1, preparation of Rosella enterica recombinant flagellin RI-flagellin

[0049] 1. Construction of a prokaryotic expression vector for the recombinant flagellin RI‐flagellin from Rosella enterica

[0050] 1) The gene encoding the recombinant flagellin RI-flagellin of Rosella enterica was artificially synthesized. Its nucleotide sequence is shown in SEQ NO.2 in the sequence listing, and its length is 1509bp. It was synthesized by Detai Biotechnology (Nanjing) Co., Ltd. The synthesized gene was detected by 2% agarose gel electrophoresis, and the detection result showed that the target gene of 1509 bp was obtained, which was consistent with the expected result.

[0051] 2) Construction of the recombinant expression vector Flagelllin-pET30a (+) (Flagellin represents the RI-flagellin coding sequence of the present invention)

[0052] a) PCR amplification of the RI-flagellin coding sequence

[0053] A 1509bp encoding gene of Rosia enterica recombinant flagellin wa...

Embodiment 2

[0104] Example 2. Verification of the prevention and treatment effect of Rosella enterica recombinant flagellin on inflammatory bowel disease

Images